5-Amino-1MQ vs Tirzepatide
A small-molecule NNMT inhibitor studied in animals for fat loss and NAD+ metabolism.
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
5-Amino-1MQ
N/A
Tirzepatide
5–10 mg
Frequency
5-Amino-1MQ
No human dose established
Tirzepatide
Once weekly
Administration
5-Amino-1MQ
Subcutaneous injection
Tirzepatide
Subcutaneous injection
Cycle length
5-Amino-1MQ
8-12 weeks (community-reported; no human trial data)
Tirzepatide
Ongoing/indefinite
Onset speed
5-Amino-1MQ
Not established in humans; gradual over weeks in animal studies
Tirzepatide
Moderate (1-2 weeks)
Evidence level
5-Amino-1MQ
Preclinical only (animal and lab studies; no human trials)
Tirzepatide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Fat and weight reduction
Metabolic markers
NAD+ / cellular energy
Human evidence
Weight Loss
Appetite Control
Blood Sugar Control
Compound specifications
5-Amino-1MQ
Molecular formula
C10H11N2+ (cation); commonly supplied as the iodide salt (C10H11IN2)
Molecular weight
159.21 g/mol (cation); 286.11 g/mol (iodide salt)
Half-life
Not established in humans; preclinical rodent data suggest a few hours (compound is membrane-permeable and orally active)
Bioavailability
Orally bioavailable in animal studies (high membrane permeability shown by PAMPA and Caco-2 assays); human data not established
CAS number
42464-96-0 (salt form)
Tirzepatide
Molecular formula
C225H348N48O68
Molecular weight
4813.45 g/mol
Half-life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS number
2023788-19-2
Dosing compared
5-Amino-1MQ
50 – 150 mg/day (community-reported, no trial)
Once daily, per community protocols · Undefined — no human study has run any duration
This is not a dose anyone established; it is the range people report using. The absence of human data here was checked rather than assumed: PubMed has no record under "5-amino-1MQ" and no clinical study of any NNMT inhibitor in people, ClinicalTrials.gov has no registered study of either the compound or the target, and no company has announced a clinical programme. The EU and WHO trial registries were not searched directly, so a trial registered only outside the US cannot be ruled out. With no human trial, there is no human safety data and no established human maximum, so there is nothing to describe any of these figures as tolerated against. It is shown as a single range rather than as starting, standard and advanced steps because no study set those steps — whether people using it escalate through them is a question about community practice that has not been checked here. The numbers that do exist are animal data only and do not convert to a human dose: mice received about 34 mg/kg a day by subcutaneous injection, 20 mg/kg three times daily for 11 days, n=9 [1]. In a dose-escalation study spanning 10 to 150 mg/kg/day, 60 mg/kg/day produced no observable adverse effects — in TWO mice [1]. Lab screening found off-target monoamine oxidase-A inhibition at higher concentrations, so caution with MAO-sensitive drugs and foods is reasonable [2], and the compound is cytotoxic to cultured pre-adipocytes at high concentration — about 40% loss of viability at 600 µM against none at 10 µM [1].
Tirzepatide
Subcutaneous injection
First 4 weeks
2.5 mg
Once weekly · First 4 weeks
FDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
Increase by 2.5 mg after at least 4 weeks at each dose
5-10 mg
Once weekly · Increase by 2.5 mg after at least 4 weeks at each dose
Per FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
Ongoing maintenance
12.5-15 mg
Once weekly · Ongoing maintenance
15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].
Best suited for
5-Amino-1MQ
Fat loss research
The clearest, most repeated finding: obese mice lost body weight and fat mass on 5-Amino-1MQ without eating less [1][2]. This is the main reason people are interested — though it is animal data, not human proof.
Metabolic health support
In mice, it improved blood sugar, insulin, and liver fat [2]. Researchers see NNMT inhibition as a promising angle for metabolic syndrome [4].
NAD+ and cellular energy science
By blocking NNMT, it raises NAD+ and SAM inside cells, which supports how cells make and use energy [1][4]. This makes it interesting to people studying aging and metabolism.
Tirzepatide
People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].
Side effects
5-Amino-1MQ
Common
- No verified human side effects
- Mild nausea or headache (community-reported)
Uncommon
- Fatigue or flushing (community-reported)
Serious
- Possible off-target MAO-A effects (theoretical)
- Unknown long-term and human risks
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Safety & evidence
5-Amino-1MQ
Evidence level
Preclinical only (animal and lab studies; no human trials)
FDA status
Research compound — not FDA approved
Safety overview
The honest picture: nobody has run a human safety trial on 5-Amino-1MQ, so everything below is from mice and cultured cells. In the 11-day mouse study, 9 treated animals lost 2.0 ± 0.6 g of body weight (about 5.1% from baseline) while 9 controls gained 0.6 ± 0.4 g, with no difference in food intake and no observable adverse effects reported [1]. The tolerability ceiling people quote comes from a dose-escalation study spanning 10 to 150 mg/kg/day in TWO mice, where 60 mg/kg/day produced no observable adverse effects [1] — a denominator worth seeing before treating it as a safety margin. In cultured pre-adipocytes the compound is cytotoxic at high concentration: no effect on viability at 10 µM, modest cytotoxicity from 100 to 300 µM, and roughly 40% loss of viability at 600 µM [1]. Lab screening also found off-target inhibition of monoamine oxidase-A at higher concentrations [2]. Short studies in mice cannot rule out problems that appear over months or years in people. Treat this as an experimental compound and talk to a doctor first, particularly if you take any medication.
Contraindications
- No human safety data exists — all evidence is from animals and lab work
- Pregnancy or breastfeeding
- Use with MAO-A-sensitive medications, given off-target MAO-A inhibition seen in lab screening [2]
Tirzepatide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
- History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication
Which is right for you?
Choose 5-Amino-1MQ if...
- Fat loss (research context)
- Metabolic health support
- NAD+ and cellular energy metabolism
Choose Tirzepatide if...
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement